Dual serotonin and noradrenaline uptake inhibitor class of antidepressants potential for greater efficacy or just hype? (Q34701029)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12079200%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

review article

1 reference

title

Dual serotonin and noradrenaline uptake inhibitor class of antidepressants potential for greater efficacy or just hype? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12079200%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

0 references

1 reference

David T Wong

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12079200%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

Frank P Bymaster

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12079200%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

publication date

1 January 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12079200%20AND%20SRC:MED&resulttype=core&format=json

Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques

10 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12079200%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

volume

58

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12079200%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

page(s)

169-222

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12079200%20AND%20SRC:MED&resulttype=core&format=json

Comparison of fluoxetine and desipramine in depressed outpatients

10 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

The role of norepinephrine in the treatment of depression

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Fluoxetine compared with imipramine in the treatment of inpatient depression. A multicenter trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Selective serotonin reuptake inhibitor efficacy in severe and melancholic depression

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Efficacy of SSRIs and Newer Antidepressants in Severe Depression

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Can the effects of antidepressants be observed in the first two weeks of treatment?

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Comparing onset of effect of antidepressants: Pragmatic considerations on methods and end-points

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

How fast are antidepressants?

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

LY227942, an inhibitor of serotonin and norepinephrine uptake: biochemical pharmacology of a potential antidepressant drug

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Duloxetine (LY 248686): an inhibitor of serotonin and noradrenaline uptake and an antidepressant drug candidate.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

A selective inhibitor of serotonin uptake: Lilly 110140, 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

dl-N-methyl-3-(o-methoxyphenoxy)-3-phenylpropylamine hydrochloride, Lilly 94939, a potent inhibitor for uptake of norepinephrine into rat brain synaptosomes and heart

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

The biochemistry of affective disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

The catecholamine hypothesis of affective disorders: a review of supporting evidence

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Norepinephrine in depressive reactions. A review

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Combination treatment with noradrenalin and serotonin reuptake inhibitors in resistant depression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

A possible common mechanism of action of antidepressant treatments: reduction in the sensitivity of the noradrenergic cyclic AMP gererating system in the rat limbic forebrain

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Subsensitivity of the norepinephrine receptor-coupled adenylate cyclase system in brain: Effects of Nisoxetine versus fluoxetine

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Chronic effects of fluoxetine, a selective inhibitor of serotonin uptake, on neurotransmitter receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Down-regulation of beta-adrenergic receptors following repeated injections of desmethylimipramine: permissive role of serotonergic axons.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Down-regulation of beta-adrenoceptors in rat cortex by repeated administration of desipramine, electroconvulsive shock and clenbuterol requires 5-HT neurones but not 5-HT.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

A strong influence of serotonin axons on beta-adrenergic receptors in rat brain.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Rapid down regulation of beta-adrenoceptors by co-administration of desipramine and fluoxetine

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Suppression of firing activity of 5-HT neurons in the dorsal raphe by alpha-adrenoceptor antagonists

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Electrophysiological and pharmacological characterization of serotonergic dorsal raphe neurons recorded extracellularly and intracellularly in rat brain slices

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Effects of venlafaxine on extracellular concentrations of 5-HT and noradrenaline in the rat frontal cortex: augmentation via 5-HT1A receptor antagonism

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Studies on the role of 5-HT1A autoreceptors and alpha 1-adrenoceptors in the inhibition of 5-HT release--I. BMY7378 and prazosin

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Suppression of serotogenic neuronal firing by α-adrenoceptor antagonists: Evidence against gaba mediation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

LY248686, a new inhibitor of serotonin and norepinephrine uptake.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Biochemical profile of midalcipran (F 2207), 1-phenyl-1-diethyl-aminocarbonyl-2-aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Norfluoxetine enantiomers as inhibitors of serotonin uptake in rat brain.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Pharmacological profile of antidepressants and related compounds at human monoamine transporters

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Fluoxetine and two other serotonin uptake inhibitors without affinity for neuronal receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Binding of antidepressants to human brain receptors: focus on newer generation compounds

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Antagonism of the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells by antidepressants and antihistaminics

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Sustained administration of the antidepressant venlafaxine in rats: pharmacokinetic and pharmacodynamic findings

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Inhibition of 5-HT cell firing in the DRN by non-selective 5-HT reuptake inhibitors: studies on the role of 5-HT1A autoreceptors and noradrenergic mechanisms.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors: electrophysiological studies in the rat brain

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Enhancement of fluoxetine-dependent increase of extracellular serotonin (5-HT) levels by (-)-pindolol, an antagonist at 5-HT1A receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Alpha 2-adrenoceptor modulation of rat ventral hippocampal 5-hydroxytryptamine release in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Venlafaxine: acute and chronic effects on 5-hydroxytryptamine levels in rat brain in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Modulation of the extracellular 5-hydroxytryptamine brain concentrations by the serotonin and noradrenaline reuptake inhibitor, milnacipran. Microdialysis studies in rats.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Synthesis and biological activity of conformationally restricted analogs of milnacipran: (1S,2R)-1-phenyl-2-[(S)-1-aminopropyl]-N,N-diethylcyclopropanecarboxami de, an efficient noncompetitive N-methyl-D-aspartic acid receptor antagonist.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

(+/-)-(Z)-2-(aminomethyl)-1-phenylcyclopropanecarboxamide derivatives as a new prototype of NMDA receptor antagonists

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

The receptor antagonist MK-801 induces increases in dopamine and serotonin metabolism in several brain regions of rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Differential actions of dizocilpine (MK-801) on the mesolimbic and mesocortical dopamine systems: role of neuronal activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Functional antagonists at the NMDA receptor complex exhibit antidepressant actions

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Current perspectives on the development of non-biogenic amine-based antidepressants

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Simultaneous increases of extracellular monoamines in microdialysates from hypothalamus of conscious rats by duloxetine, a dual serotonin and norepinephrine uptake inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

WAY 100,635 enhances both the 'antidepressant' actions of duloxetine and its influence on dialysate levels of serotonin in frontal cortex.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Antagonism of serotonin 5-HT1A receptors potentiates the increases in extracellular monoamines induced by duloxetine in rat hypothalamus.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential?

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Effect of various antidepressant drugs on the spontaneous firing rate of locu coeruleus and dorsal raphe neurons of the rat

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Inhibition of median and dorsal raphe neurones following administration of the selective serotonin reuptake inhibitor paroxetine

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Effects of the two antidepressant drugs mianserin and indalpine on the serotonergic system: single-cell studies in the rat

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Venlafaxine: discrepancy between in vivo 5-HT and NE reuptake blockade and affinity for reuptake sites

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Effects of acute and chronic administration of fluoxetine on the activity of serotonergic neurons in the dorsal raphe nucleus of the rat

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Raphe neurons: effect of tricyclic antidepressant drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Inhibition of both noradrenergic and serotonergic neurons in brain by the α-adrenergic agonist clonidine

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Clozapine inhibits serotoninergic transmission by an action at alpha 1-adrenoceptors not at 5-HT1A receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Modulation of the firing activity of noradrenergic neurones in the rat locus coeruleus by the 5-hydroxtryptamine system

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Inhibition of in vitro and ex vivo uptake of noradrenaline and 5-hydroxytryptamine by five antidepressants; correlation with reduction of spontaneous firing rate of central monoaminergic neurones.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

The effects of an inhibitor of tryptophan 2,3-dioxygenase and a combined inhibitor of tryptophan 2,3-dioxygenase and 5-HT reuptake in the rat

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Effect of acute, short- and long-term milnacipran administration on rat locus coeruleus noradrenergic and dorsal raphe serotonergic neurons.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

DMI, Wy-45,030, Wy-45,881 and ciramadol inhibit locus coeruleus neuronal activity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

2-Phenyl-2-(1-hydroxycycloalkyl)ethylamine derivatives: synthesis and antidepressant activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Dose-dependent noradrenergic and serotonergic properties of venlafaxine in animal models indicative of antidepressant activity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Psychopharmacology of midalcipran, 1-phenyl-1-diethyl-amino-carbonyl-2-aminomethylcyclopropane hydrochloride (F 2207), a new potential antidepressant

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

The antinociceptive effect of venlafaxine in mice is mediated through opioid and adrenergic mechanisms

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Do antidepressants affect motivation in conditioned place preference?

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Pharmacological effects of venlafaxine, a new antidepressant, given repeatedly, on the alpha 1-adrenergic, dopamine and serotonin systems.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rat forced swimming test

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Depression: a new animal model sensitive to antidepressant treatments

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Effect of subchronic antidepressant treatments on behavioral, neurochemical, and endocrine changes in the forced-swim test

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Inhibition of mouse killing behavior by serotonin-mimetic drugs: effects of partial alterations of serotonin neurotransmission

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Venlafaxine exhibits pre-clinical antidepressant activity in the resident-intruder social interaction paradigm.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Serotonin and the neurobiology of depression. Effects of tryptophan depletion in drug-free depressed patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

A review of the efficacy of serotonergic and noradrenergic reuptake inhibitors for treatment of major depression

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

A double-blind trial of fluoxetine, 20 mg, and placebo in out-patients with DSM-III-R major depression and melancholia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Severity of depression and response to fluoxetine

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatients

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Double-blind placebo-controlled study of milnacipran in hospitalized patients with major depressive disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Controlled comparison of two doses of milnacipran (F 2207) and amitriptyline in major depressive inpatients

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

An open-label study of duloxetine hydrochloride, a mixed serotonin and noradrenaline reuptake inhibitor, in patients with DSM-III-R major depressive disorder

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8183-8_5

10.1007/978-3-0348-8183-8_5

31 March 2020

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12079200%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

1 reference